Výsledky vyhledávání - "T. Baisamut (Reungwetwattana)"

362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial

Autor: A. Tan, D-W. Kim, T. Baisamut (Reungwetwattana), L. Yueh Ni, G.F. Ho, L.M. Tho, N. Prasongsook, S. Lee, T.S.K. Mok, D.S.W. Tan, H.H.F. Loong

Publikováno v: Annals of Oncology. 33:S1582-S1583

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d19d5298f1bbab1b9863aad01b6bf8c
https://doi.org/10.1016/j.annonc.2022.10.400

Zobrazit plný text záznamu

LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

Autor: B.C. Cho, M-J. Ahn, J.H. Kang, R. Soo, T. Baisamut (Reungwetwattana), J.C-H. Yang, I. Cicin, D-W. Kim, Y-L. Wu, S. Lu, K. Lee, Y-K. Pang, A. Zimina, C.H. Fong, E. Poddubskaya, Y. Kim, T. An, H. Lee, H. Byun, B. Zaric

Publikováno v: Annals of Oncology. 33:S1560

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7771696a7a59f9f6705f2db73b24758b
https://doi.org/10.1016/j.annonc.2022.10.349

Zobrazit plný text záznamu

LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study

Autor: C. Zhou, Y. Lu, S-W. Kim, T. Baisamut (Reungwetwattana), J. Zhou, Y. Zhang, J. He, J. Yang, Y. Cheng, S-H. Lee, J. Chang, J. Fang, Z. Liu, L. Bu, L. Qian, T. Xu, V. Archer, M. Hilton, M. Zhou, L. Zhang

Publikováno v: Annals of Oncology. 33:S1563

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::337533fb14f97881774ebc719c680a0f
https://doi.org/10.1016/j.annonc.2022.10.353

Zobrazit plný text záznamu